Xtandi (Enzalutamide)

Xtandi (Enzalutamide) is a next-generation androgen receptor inhibitor developed for the treatment of various stages of prostate cancer. It is designed to interfere with androgen receptor signaling, a critical pathway that drives the growth and survival of prostate cancer cells. By blocking the effects of androgens such as testosterone, Xtandi helps slow disease progression and improve clinical outcomes in patients with advanced prostate cancer.

Xtandi is indicated for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-resistant prostate cancer (mCRPC). It may be used in combination with androgen deprivation therapy (ADT) or as part of a comprehensive treatment strategy determined by healthcare professionals.

Administered orally once daily, Xtandi offers patients a convenient treatment option supported by extensive clinical evidence demonstrating improvements in overall survival, progression-free survival, and delay in disease progression. Its efficacy across multiple stages of prostate cancer has made it a cornerstone therapy in modern genitourinary oncology.

As an advanced targeted therapy, Xtandi represents a significant advancement in prostate cancer management by delivering precise inhibition of androgen receptor signaling while providing patients with an effective and well-established treatment option. It continues to play an important role in improving patient outcomes and advancing the standard of care in prostate cancer treatment worldwide.